Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Colonic Neoplasms
  • Neoplasm Recurrence, Local

abstract

  • These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.

publication date

  • March 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4872008

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.63.0558

PubMed ID

  • 26811529

Additional Document Info

start page

  • 843

end page

  • 53

volume

  • 34

number

  • 8